- CA$14.18m
- CA$14.42m
- CA$13.85m
- 66
- 68
- 20
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.34 | ||
| Price to Tang. Book | 8.46 | ||
| Price to Free Cashflow | 11.82 | ||
| Price to Sales | 1.02 | ||
| EV to EBITDA | 13.98 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.76% | ||
| Return on Equity | -5% | ||
| Operating Margin | -2.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 9.54 | 10.57 | 11.84 | 12.78 | 13.85 | n/a | n/a | 14.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +107.3 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NexgenRx Inc. is a Canada-based third-party administrator and technology solutions provider. The Company is focused on building technology platforms that equip its clients with unprecedented capabilities for managing and self-managing group benefit plans, group pension plans and patient support programs. The Company offers plan sponsors, administration and health benefit technology applications in a of software-as-a-service model. The Company’s products include NexSys, NexAdmin, NexPension and NexPSPAssist. The NexSys product platform provides solution and simplifies adjudication of dental, prescription drug and extended health claims. Its NexAdmin product enables sponsors to take complete control of benefit plan administration. Its NexPension product is an advanced pension administration solution designed to help sponsors record and tabulate contributions for their membership group in a multi-employer environment. Its platform makes self-administration a reality.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 13th, 2003
- Public Since
- September 14th, 2006
- No. of Employees
- 20
- Sector
- Investment Banking & Investment Services
- Industry
- Financials
- Exchange
TSX Venture Exchange- Shares in Issue
- 70,921,820
- Address
- 191 The West Mall, Suite 905, TORONTO, M9C 5L6
- Web
- https://www.nexgenrx.com/
- Phone
- +1 4166953393
- Contact
- Ronald Loucks
- Auditors
- Grant Thornton LLP
Upcoming Events for NXG
NexgenRx Inc Extraordinary Shareholders Meeting
NexgenRx Inc Annual Shareholders Meeting
NexgenRx Inc Annual Shareholders Meeting
Q2 2024 NexgenRx Inc Earnings Release
Similar to NXG
49 North Resources
TSX Venture Exchange
AI Artificial Intelligence Ventures
TSX Venture Exchange
Alset Capital
TSX Venture Exchange
Banxa Holdings
TSX Venture Exchange
Bitcoin Well
TSX Venture Exchange
FAQ
What is the NexgenRx share price?
As of Today at 19:15 UTC, shares in NexgenRx are trading at CA$0.20. This share price information is delayed by 15 minutes.
How has the NexgenRx share price performed this year?
Shares in NexgenRx last closed at CA$0.20 and the price had moved by -42.03% over the past 365 days. In terms of relative price strength the NexgenRx share price has underperformed the Toronto Stock Exchange 300 Composite Index by -44.99% over the past year.
What are the analyst and broker recommendations for NexgenRx?
There is no consensus recommendation for this security.
What is the NexgenRx dividend yield?
The NexgenRx dividend yield is 5% based on the trailing twelve month period.
Does NexgenRx pay a dividend?
Last year, NexgenRx paid a total dividend of CA$0.01, and it currently has a trailing dividend yield of 5%. We do not have any data on when NexgenRx is to next pay dividends.
When does NexgenRx next pay dividends?
We do not have data on when NexgenRx is to next pay dividends. The historic dividend yield on NexgenRx shares is currently 5%.
How do I buy NexgenRx shares?
To buy shares in NexgenRx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NexgenRx?
As of the previous close price of CA$0.20, shares in NexgenRx had a market capitalisation of CA$14.18m.
Where are NexgenRx shares listed?
Here are the trading details for NexgenRx:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: NXG
What kind of share is NexgenRx?
Based on an overall assessment of its quality, value and momentum NexgenRx is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NexgenRx share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the NexgenRx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NexgenRx. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -22.36%.
As of the last closing price of CA$0.20, shares in NexgenRx were trading -32.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NexgenRx PE Ratio?
The NexgenRx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NexgenRx?
NexgenRx's management team is headed by:
- Thomas Corcoran - NEC
- Ronald Loucks - PRE
- Kelly Ehler - CFO
- Hugh Hart - VPR
- Charles Burns - IND
- Randy McGlynn - IND